Zeyuan Yu

机构：Fujian Medical University, First Affiliated Hospital of Fujian Medical University, Lanzhou University Second Hospital, Lanzhou University · ORCID：0000-0002-7814-5416

发表论文 63 篇 · 总被引 862 次 · h-index 16

代表论文

• KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC (2025 · Cell Reports Medicine · 被引 20)
• Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma: A multicenter, phase 2 study (2024 · Med · 被引 19)
• Targeting UBE2T suppresses breast cancer stemness through CBX6-mediated transcriptional repression of SOX2 and NANOG (2024 · Cancer Letters · 被引 15)
• Targeting NUF2 suppresses gastric cancer progression through G2/M phase arrest and apoptosis induction (2024 · Chinese Medical Journal · 被引 11)
• PLXNA1 confers enzalutamide resistance in prostate cancer via AKT signaling pathway (2024 · Neoplasia · 被引 10)
• Reciprocal regulation between RACGAP1 and AR contributes to endocrine therapy resistance in prostate cancer (2024 · Cell Communication and Signaling · 被引 10)